What You Ought to Know:
– Flatiron Health, a healthtech firm targeted on reworking medical analysis by expertise that integrates analysis into on a regular basis care, has introduced a strategic partnership with Massive Bio, a world chief in utilizing synthetic intelligence to streamline affected person identification and recruitment for medical trials.
– The partnership goals to develop affected person identification capabilities and enhance medical trial enrollment throughout the U.S.
Improve Affected person Identification Capabilities and Providers
This collaboration will make the most of Large Bio’s U.S.-based database to establish sufferers who could also be eligible for medical trials however will not be at present enrolled and are positioned close to collaborating trial websites. These sufferers will then be referred to Flatiron’s analysis websites, the place they are often onboarded as new sufferers and evaluated for potential trial enrollment utilizing Flatiron’s expertise and centralized affected person identification companies.
“At Large Bio, our mission is to make entry to medical trials really patient-centric, making certain the suitable affected person is matched to the suitable trial on the proper time—irrespective of the place they reside,” mentioned Dr. Arturo Loaiza-Bonilla, Co-Founder and Chief Medical Officer at Large Bio. “By pairing our AI-driven platform and concierge companies with Flatiron Well being’s intensive analysis infrastructure, we may help physicians and care groups expedite trial enrollment, cut back disparities in entry, and enhance outcomes for extra sufferers.”
